Drug Profile
Didanosine/hydroxycarbamide
Alternative Names: ddI/HU - Virostatics; Didanosine/hydroxyurea - Virostatics; VS 411Latest Information Update: 04 Mar 2011
Price :
$50
*
At a glance
- Originator Virostatics
- Class Antianaemics; Antineoplastics; Antiretrovirals; Dideoxynucleosides; Purine nucleosides; Ribonucleosides; Urea compounds
- Mechanism of Action DNA synthesis inhibitors; Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued HIV-1 infections
Most Recent Events
- 02 Mar 2011 Discontinued - Phase-II for HIV-1 infections in Argentina, Uganda, Russia and Italy (PO)
- 02 Mar 2011 Efficacy data from a phase II trial in HIV-1 infections released by Virostatics
- 19 Jul 2010 Efficacy and adverse events data from a phase II trial in HIV-1 infections presented at the 18th International AIDS Conference (IAC-2010)